Skip to content
Screener

Ginkgo Bioworks DNA Pre-Tax Income

Pre-Tax Income at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$1.92B
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$58.97M-62.2%
eXoZymes, Inc. logo
eXoZymes, Inc.EXOZ
-$2.37M-27.7%
TEC
Bio-TechneTECH
$71.23M+86.1%
Revvity logo
RevvityRVTY
$63.53M-7.5%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$166.3M-890%

Segments

By segment

See full
Reportable Segment-$57.19M-6.9%

Other financials

Income statement

See full
Revenue$20.2M-48.5%
Gross profit$18.4M-45.4%
Operating income-$58.5M-0.7%
Net income-$46.7M+22.5%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$172.0M-31.6%
Total debt$404.1M-5.8%
Total equity$420.3M-31.4%
Total assets$990.0M-19.6%

Cash flow

See full
Operating cash flow-$44.3M-10.0%
CapEx$2.6M+6,792%
Free cash flow-$46.9M-16.4%

Valuation

See full
Market cap$520.64M-26.8%
Enterprise value$752.73M-15.2%
P/S4.7×+1.3×

Profitability

See full
Gross margin91.8%
Operating margin-259.9%+1,304pp
Net margin-260%+718pp
FCF margin-156.3%+38.7pp

Returns & leverage

See full
Return on equity-56.3%+23.1pp
Debt / equity+0.3×
Current ratio4.6×-0.8×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054298
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gain (loss) on investments1,987(229)773(3,922)
Other income (expense), net809(1,168)(6,338)(5,806)
Total other income (expense)1,3554,686(3,410)2,436
Loss from continuing operations before income taxes(57,193)(53,477)(133,332)(136,699)
Income tax (benefit) expense128(283)48(195)
Net loss from continuing operations$(57,321)$(53,194)$(133,380)$(136,504)
Net income (loss) from discontinued operations, net of tax10,611(7,106)4,083(14,753)
Net loss$(46,710)$(60,300)$(129,297)$(151,257)

Item 1. Financial Statements (Unaudited)

FAQ

What is Ginkgo Bioworks's pre-tax income?
Ginkgo Bioworks (DNA) reported pre-tax income of -$57.19M in Q2 2026.
How has Ginkgo Bioworks's pre-tax income changed year-over-year?
Ginkgo Bioworks's pre-tax income decreased by 6.9% year-over-year, from -$53.48M to -$57.19M.
What is the long-term trend for Ginkgo Bioworks's pre-tax income?
Over 4 years (2021 to 2025), Ginkgo Bioworks's pre-tax income has grown at a -36.5% compound annual growth rate (CAGR), from -$1.84B to -$298.85M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Ginkgo Bioworks's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude